Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase

OBJECTIVE: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs. They inactivate incretin hormones but also have many other effects throughout the body, among which are effects on the immune system. This might result in an increased infection risk. This study assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Willemen, Marjolein J., Mantel-Teeuwisse, Aukje K., Straus, Sabine M., Meyboom, Ron H., Egberts, Toine C., Leufkens, Hubert G.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024351/
https://www.ncbi.nlm.nih.gov/pubmed/21270195
http://dx.doi.org/10.2337/dc10-1771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024351/
https://www.ncbi.nlm.nih.gov/pubmed/21270195
http://dx.doi.org/10.2337/dc10-1771

Ejemplares similares